THERESA MANRIQUEZ: Open Payments
NPI 1578170791 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,612 in 203 payments from 14 companies in 2025. Trend: 2023 $3,470 · 2024 $3,811 · 2025 $3,612
Food & beverage: $3,612
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $475 |
| ABBVIE INC. | 21 | $445 |
| Janssen Biotech, Inc. | 19 | $353 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 34 | $330 |
| QOL Medical, LLC | 13 | $326 |
| Aimmune Therapeutics, Inc. | 23 | $285 |
| Celltrion USA Inc. | 18 | $276 |
| Gilead Sciences, Inc. | 11 | $263 |
| Ardelyx, Inc. | 11 | $235 |
| GENZYME CORPORATION | 7 | $187 |
Products named: TREMFYA, Sucraid, ENTYVIO, ZENPEP, VEGZELMA, XIFAXAN, IBSRELA, RINVOQ.
Industry payments across TX — which companies pay providers there.
